Perphenazine

• 

  Subject Areas on Research

  • Anorexia nervosa: a combined therapeutic approach. 
  • Bl-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study. 
  • Comparison of outcomes for African Americans, Hispanics, and Non-Hispanic Whites in the CATIE study. 
  • Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. 
  • Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. 
  • Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. 
  • Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. 
  • Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. 
  • Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. 
  • Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. 
  • Introduction to the CATIE special section. 
  • Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. 
  • Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia. 
  • Results of phase 3 of the CATIE schizophrenia trial. 
  • The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. 
  • The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial. 
  • Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. 
  • Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. 
  • What CATIE found: results from the schizophrenia trial.